Salivary testing represents more than a new tool; it’s a scalable strategy to shift care upstream, reduce preventable emergencies, and bring equity to a population too often left behind.
A new report from the Private Equity Stakeholder Project reveals that private equity firms have been increasingly acquiring intellectual and developmental disability providers and implementing cost-cutting strategies that reduce care quality.
CEO and neuroscientist Dr. Iftach Dolev on how the new device can bring a powerful tool to psychiatrists and neurologists alike.